FDA Grants Breakthrough Therapy Designation to DT120 ODT for Major Depressive Disorder: Phase 3 Evidence Highlights Rapid and Durable Antidepressant Effects
Abstract
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to DT120 orally disintegrating tablet (ODT; lysergide/LSD) for the treatment of major depressive disorder (MDD) following preliminary clinical evidence demonstrating significant antidepressant efficacy. The designation follows a prior BTD awarded for generalized anxiety disorder (GAD), underscoring the potential of DT120 ODT to address substantial unmet needs in psychiatric care. Data from the phase 3 Emerge and Panorama trials suggest that a single administration of DT120 ODT may produce rapid, clinically meaningful, and durable improvements in depressive and anxiety symptoms, with effects extending up to 12 weeks after treatment.
Introduction
Definium Therapeutics announced that the FDA has awarded Breakthrough Therapy Designation to DT120 ODT, a pharmaceutically optimized formulation of lysergide (LSD), for the treatment of adults with MDD. The designation was based on preliminary clinical findings demonstrating significant improvements in depression symptoms following a single treatment session.
This development adds to the drugโs regulatory momentum, as DT120 ODT had previously received Breakthrough Therapy Designation for the treatment of GAD. According to Definium executives, the dual designations reflect both the substantial unmet clinical burden associated with these disorders and the potential for DT120 ODT to provide benefits beyond those achievable with currently available therapies.
Expert Perspective
Discussing the significance of the FDAโs decision, Dan Karlin, MD, MA, Chief Medical Officer of Definium Therapeutics, stated:
โThereโs the potential that we could do something that current treatment canโt do to address morbidity and mortality associated with the illness.โ
Karlin emphasized that the FDAโs recognition reflects the possibility that DT120 ODT may address major limitations of existing pharmacologic treatments for both depression and anxiety disorders.
Mechanism of Action and Formulation Characteristics
DT120 ODT is an orally disintegrating formulation of LSD designed to optimize pharmaceutical delivery. The agent functions primarily as a partial agonist at serotonin 5-HT2A receptors, a target believed to contribute to its therapeutic and neuropsychological effects.
Compared with conventional formulations, DT120 ODT has been engineered to provide:
- Rapid absorption
- Enhanced bioavailability
- Reduced gastrointestinal adverse effects
- Consistent treatment-session dynamics
These characteristics are intended to improve both the patient experience and therapeutic outcomes.
Phase 3 EMERGE Trial in Major Depressive Disorder
Study Overview
The EMERGE trial was a phase 3, randomized, double-blind, placebo-controlled study evaluating DT120 ODT in adults diagnosed with MDD.
Topline results, announced in June, showed that treatment with a single dose of DT120 ODT resulted in statistically significant improvements in depressive symptoms compared with placebo.
Primary Findings
Participants receiving DT120 ODT demonstrated significant reductions in:
- Total Montgomery-ร sberg Depression Rating Scale (MADRS) scores
- Depressed mood
- Anhedonia
- Other core depressive symptoms
According to Karlin, therapeutic benefits emerged rapidly and remained durable.
โThe drugโs not still there 12 weeks later, and the person feels different. The very mechanisms in their brain that create the ruminations of depression or the anxious anticipation of GAD are just working a bit differently.โ
Notably, antidepressant effects were observed as early as week 1 and persisted throughout the 12-week assessment period, suggesting both rapid onset and long-lasting efficacy after a single administration.
Clinical Significance
Karlin noted that improvements observed in MADRS scores represent clinically meaningful changes in critical domains of depression, including mood regulation and motivation, outcomes that are likely to be central for eventual regulatory review and approval decisions.
He further suggested that future evaluations should extend beyond traditional symptom-rating scales to assess real-world functioning and quality of life.
โThe people we treat with DT120 who get a lot better from it donโt tend to talk in terms of symptom suppression.โ
Rather than merely reducing symptoms, patients often describe broader changes in self-perception and life outlook.
โThey tend to talk in terms of having a different perspective on their life, of feeling truly different, which is not something I could say about how people feel when they get treated with the current existing drugs like SRIs.โ
Table 1. Key Findings From the Phase 3 EMERGE Trial in MDD
| Parameter | Finding |
|---|---|
| Study design | Randomized, double-blind, placebo-controlled phase 3 trial |
| Population | Adults with major depressive disorder |
| Intervention | Single dose DT120 ODT |
| Primary assessment tool | Montgomery-ร sberg Depression Rating Scale (MADRS) |
| Initial response | Significant improvement by Week 1 |
| Durability | Effects maintained through Week 12 |
| Key outcomes | Improvement in depressed mood, anhedonia, and overall depressive symptoms |
| Safety findings | Generally well tolerated; no new safety signals identified |
Phase 3 PANORAMA Trial in Generalized Anxiety Disorder
Study Design
The Panorama trial was a randomized, double-blind, placebo-controlled phase 3 study evaluating DT120 ODT in adults with GAD.
Enrollment and Randomization
A total of 245 adults aged 18โ74 years were enrolled and assigned in a 2:1:2 ratio to one of three groups:
| Treatment Group | Number of Participants |
|---|---|
| DT120 ODT 100 ยตg | 96 |
| DT120 ODT 50 ยตg (control dose) | 52 |
| Placebo | 97 |
| Total | 245 |
Primary Efficacy Results
The study successfully met its primary endpoint, demonstrating statistically significant reductions in anxiety severity as measured by the Hamilton Anxiety Rating Scale (HAM-A).
Table 2. HAM-A Outcomes at Week 12
| Outcome | DT120 ODT 100 ยตg | Placebo |
|---|---|---|
| Least Squares Mean Change | โ9.8 points | โ4.7 points |
| LS Mean Difference | -5.1 points | โ |
| P value | < .0001 | โ |
Week 1 Results
| Outcome | Result |
|---|---|
| LS Mean Difference vs placebo | โ5.3 points |
| P value | < .0001 |
These findings indicate that anxiety improvement occurred rapidly, within one week, and remained significant through week 12.
Safety and Tolerability
Across both the EMERGE and PANORAMA trials, DT120 ODT demonstrated a favorable safety profile.
Table 3. Safety Summary Across Phase 3 Studies
| Safety Parameter | Observation |
|---|---|
| Overall tolerability | Generally well tolerated |
| Severity of adverse events | Mostly mild-to-moderate |
| Timing of adverse effects | Predominantly on dosing day |
| New safety signals | None identified |
| Suicidal ideation or behavior | No increase observed |
| Total 100-ยตg treatment sessions conducted | >1,000 |
Commenting on the accumulated safety experience, Karlin stated:
โThe session dynamics just continue to be incredibly consistent, and the drug is highly tolerable.โ
He further added:
โThose session dynamics, the patient experience, the remarkable efficacy, all of that adds up to us being incredibly enthusiastic about the clinical potential of this drug in the real world if approved.โ
Future Directions
Definium Therapeutics is continuing development of DT120 ODT through several ongoing and planned studies.
Current Activities
| Program | Status |
|---|---|
| EMERGE Part B | Ongoing 40-week extension |
| PANORAMA Part B | Ongoing 40-week extension |
| ASCEND (second phase 3 MDD study) | Recruiting |
| Phase 3 PTSD study | Planned for 2027 |
| New Drug Application (NDA) submission | Planned for first half of 2027 |
The extension phases allow participants to receive up to four open-label DT120 ODT treatments, enabling further evaluation of long-term safety and effectiveness.
Conclusion
The FDAโs decision to grant Breakthrough Therapy Designation for DT120 ODT in MDD represents a significant regulatory milestone for Definium Therapeutics and for psychedelic-based psychiatric therapeutics more broadly. Findings from the phase 3 EMERGE and PANORAMA studies indicate that a single administration of this optimized LSD formulation may produce rapid and sustained reductions in depressive and anxiety symptoms, with a favorable tolerability profile. As additional confirmatory studies progress and regulatory submissions move forward, DT120 ODT may emerge as a novel treatment option for patients with MDD, GAD, and potentially PTSD.
